Research

Completed Trials (both are industry trials):

• Phase 3, double blind, randomized, controlled, study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 mth) in healthy adult female subjects aged 26 years and above (HPV-015) (2009-2014) (NCT00294047) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00294047.
• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (Morab-0003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive-Ovarian Cancer in First Relapse. (2009-2012) (NCT00849667) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00849667.

Ongoing Trials:

• Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO) – 2014 - (NCT02078544) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT02078544.
• A Randomized Phase II / III Trial of Intravenous (IV) paclitaxel weekly plus (IV) Carboplatin once every 3 weeks versus IV paclitaxel weekly plus intraperitoneal (IP) carboplatin once every 3 weeks in women with epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer – 2014, collaboration with Japan (GOTIC and JGOG) - (NCT01506856) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT01506856.
• An Open-Label, Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Multiply Recurrent Epithelial Ovarian Cancer – 2016 – (NCT02736305) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT02736305.
• Phase II Study of Vinorelbine in Stem-A/C5-like Subtype Platinum Resistant Ovarian Cancer (VIP trial) – 2017, collaboration with Australia (ANZGOG) – (NCT03188159) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03188159.
• A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients with Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin – 2017 – (NCT03100006) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03100006.
• A Multicentre Phase II randomised trial of MEDI4736 (DURVALUMAB) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas – 2018, collaboration with Korea (KGOG) and Australia (ANZGOG) (NCT03405454) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03405454.
• A phase I study of low dose whole abdominal radiation therapy (LDWART) with weekly paclitaxel for platinum resistant ovarian cancer (NCT02545010) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT02545010. (Phase I completed and published, pending Phase II)
• Phase I study of Combined Medi4736 (Durvalumab, PD-L1 inhibitor), PARP inhibitor (Olaparib), and AKT inhibitor (AZD5363) in Solid Tumours (MediPAC Study) - 2018- (NCT03772561) For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT03772561?term=NCT03772561&draw=2&rank=1. 
• Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) - 2020 - (NCT04620954). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04620954?term=Orion02&draw=2&rank=1.
• A single-arm phase II study of Olaparib maintenance with Pembrolizumab & Bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01) - 2020, collaboration with Korea (KGOG) - (NCT04361370). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04361370?term=NCT04361370&draw=2&rank=1.

• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) - 2020 - (NCT04269200). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04269200?term=DUO-E+trial&draw=2&rank=1.

• A Multicentre Phase II trial of  Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas (LARA) - 2021 - (NCT04699071). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04699071?term=LARA&cntry=SG&draw=2&rank=1.
• Phase III Randomized, Open-label, Active-controlled Study of Alpelisib Plus Olaparib in Platinum-Resistant, High-grade Serous OC (EPIK-O) - 2021 - (NCT04729387). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04729387?term=NCT04729387&draw=2&rank=1.
• Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) - 2021 - (NCT04697628). For more information on the trial, please access the link, https://www.clinicaltrials.gov/ct2/show/NCT04697628?term=NCT04697628&draw=2&rank=1.